Bioinvent International AB | Ownership
Companies that own Bioinvent International AB
Rhenman & Partners Asset Management AB
10,048,316
2.86%
3,768,117
0.2%
12/31/2016
SEB Investment Management AB
9,562,259
2.73%
9,562,259
0.01%
09/30/2017
MFS International (UK) Ltd.
4,350,077
1.24%
0
0%
07/31/2018
Alfred Berg Kapitalförvaltning AB
1,850,000
0.53%
0
0.02%
07/31/2018
Dimensional Fund Advisors LP
746,468
0.21%
-99,589
0%
04/30/2018
Skandia Investment Management AB
138,268
0.04%
0
0%
07/31/2018
Catella Fondförvaltning AB
77,034
0.02%
0
0%
08/31/2018
Nomura Asset Management Co., Ltd.
38,894
0.01%
-15,874
0%
12/31/2016
Xact Kapitalförvaltning AB
160
0%
-1,604,214
0%
08/31/2018
E. Öhman J :or Fonder AB
0
0%
-198,088
0%
12/31/2017
| Address |
Sölvegatan 41
Lund SN 223 70
Sweden
|
|
Employees
|
- |
| Website |
http://www.bioinvent.com |
| Updated |
07/08/2019 |
| BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F. |
